About entrada therapeutics inc - TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which provides of a class of medicines that engages in intracellular targets. Its Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The company was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.
TRDA At a Glance
Entrada Therapeutics, Inc.
One Design Center Place
Boston, Massachusetts 02210
| Phone | 1-857-520-9158 | Revenue | 25.42M | |
| Industry | Biotechnology | Net Income | -143,750,000.00 | |
| Sector | Health Technology | Employees | 152 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TRDA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.73 |
| Price to Book Ratio | 1.286 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.184 |
| Enterprise Value to Sales | 7.076 |
| Total Debt to Enterprise Value | 0.283 |
TRDA Efficiency
| Revenue/Employee | 167,243.421 |
| Income Per Employee | -945,723.684 |
| Receivables Turnover | 9.865 |
| Total Asset Turnover | 0.056 |
TRDA Liquidity
| Current Ratio | 12.525 |
| Quick Ratio | 12.525 |
| Cash Ratio | 12.12 |
TRDA Profitability
| Gross Margin | 83.887 |
| Operating Margin | -613.658 |
| Pretax Margin | -561.843 |
| Net Margin | -565.477 |
| Return on Assets | -31.814 |
| Return on Equity | -39.126 |
| Return on Total Capital | -40.259 |
| Return on Invested Capital | -34.503 |
TRDA Capital Structure
| Total Debt to Total Equity | 16.637 |
| Total Debt to Total Capital | 14.264 |
| Total Debt to Total Assets | 13.496 |
| Long-Term Debt to Equity | 15.286 |
| Long-Term Debt to Total Capital | 13.105 |